MOUNTAIN VIEW, Calif.,
Nov. 3, 2011 /PRNewswire/ -- MAP
Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the
Company will participate in the following investor conferences in
November 2011:
Credit Suisse 2011 Healthcare Conference
Thursday, November 10, at
4:00 p.m. MT in Phoenix
Lazard Capital Markets 8th Annual Healthcare Conference
Wednesday, November 16, at
10:30 a.m. ET in New York
A live webcast of each event will be available on the Investor
Relations section of MAP Pharmaceuticals' website at
http://www.mappharma.com. A replay also will be available within 24
hours for seven days following each presentation.
About MAP Pharmaceuticals
MAP Pharmaceuticals is an emerging biopharmaceutical company
focused on developing and commercializing new therapies to address
undermet patient needs in neurology. The Company is
developing LEVADEX®, an orally inhaled investigational drug for the
acute treatment of migraine. The New Drug Application for LEVADEX®
is currently under review by the U.S. Food and Drug Administration.
MAP Pharmaceuticals has entered into a collaboration
agreement with Allergan, Inc. to co-promote LEVADEX to neurologists
and pain specialists in the U.S. and Canada. The Company also applies its
proprietary drug particle and inhalation technologies to generate
new pipeline opportunities by enhancing the therapeutic benefits of
proven drugs, while minimizing risk by capitalizing on their known
safety, efficacy and commercialization history. Additional
information about MAP Pharmaceuticals can be found at
http://www.mappharma.com.
CONTACTS:
|
|
|
Nicole
Foderaro
|
Lisa Borland
|
|
WCG
|
MAP Pharmaceuticals,
Inc.
|
|
(415)
946-1058
|
650-386-3122
|
|
nfoderaro@wcgworld.com
|
lborland@mappharma.com
|
|
|
|
SOURCE MAP Pharmaceuticals, Inc.